Keywords
How to Cite
Abstract
Background. Endothelin (ET) is one of the most significant regulators of the functional state of vascular endothelium. ET‑1 is the principal cardiovascular isoform of the endothelin system. ET‑1 has both inflammatory and proliferative affects and contributes to pathogenic processes in the cardiovascular system. In diabetes, the rise of glucose concentration effects the formation of ET‑1. The aim of the work was to study the content of ET‑1 in the blood of patients with diabetes treated with various hypoglycemic agents. Material and methods. The amount of ET‑1 was evaluated via ELISA in 103 individuals: 17 healthy volunteers and 86 patients with diabetes. To determine the concentration of ET‑1 the endothelin (1-21) EIA kit (Biomedica) was used. Glycated hemoglobin was
determined using one HbA1c FS kit — DiaSys Diagnostic Systems. Results. The average level of endothelin in the blood of patients with diabetes was 0.536±0.047 fmol/ml vs. control — 0.118±0.017 fmol/ml. We did not observed changes of ET‑1 levels during monotherapy with metformin or insulin. At metformin + insulin + dapagliflosin, insulin + metformin and sulfonylurea + metformin but not DPP‑4 inhibitor + metformin combinations (T2D) there was decrease of ET‑1 level in the blood. It is of interest that DPP‑4 inhibitor + metformin caused significant increase (0.767±0.043 fmol/ml) of ET‑1 concentration. Conclusion. Thus, with combination therapy, except pair DPP‑4 inhibitor + metformin, the level of ET‑1 in the blood of patients with diabetes decreased significantly more than with monotherapy.
References
Тронько НД, Пушкарев ВМ, Соколова ЛК, Пушкарев ВВ, Ковзун ЕИ. Молекулярные механизмы патогенеза сахарного диабета и его осложнений. К.: Издательский дом Медкнига, 2018. 264 с. (Tronko ND, Pushkarev VM, Sokolova LC, Pushkarev VV, Kovzun EI. Molecular mechanisms of the pathogenesis of diabetes mellitus and its complications. K.: Medkniga Publishing House, 2018. 264 p.)
Jain A, Chen S, Yong H, Chakrabarti S. Endothelin‑1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes. J. Diabetes Metab. Disord. — 2018. — Vol. 17, N. 2. — P. 189-195. doi: 10.1007/s40200-018-0360-8.
Johnström P, Fryer TD, Richards HK, Maguire JJ, Clark JC, Pickard JD, et al. Positron emission tomography of [18F]-big endothelin‑1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin‑1 in lung and liver. Br. J. Pharmacol. — 2010. — Vol. 159. — P. 812-819. doi: 10.1111/j.1476-5381.2010.00641.x.
Johnström P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC, et al. Positron emission tomography using 18F-labelled endothelin‑1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br. J. Pharmacol. — 2005. — Vol. 144. — P. 115-122.
Kalani M. The importance of endothelin‑1 for microvascular dysfunction in diabetes. Vasc. Health Risk Manag. — 2008. — Vol. 4, N. 5. — P. 1061-1068. doi: 10.2147/vhrm.s3920.
el-Mesallamy H, Suwailem S, Hamdy N. Evaluation of C-reactive protein, endothelin‑1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm. — 2007. — Vol. 2007. — P. 73635. doi: 10.1155/2007/73635.
Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin‑1 generegulation. FASEB J. — 2011. — Vol. 25. — P. 16-28. doi: 10.1096/fj.10-161612.
Davenport AP. Endothelin. Pharmacol. Rev. — 2016. — Vol. 68, N. 2. P. 357-418. doi: 10.1124/pr.115.011833.
Chen S, Feng B, George B, Chakrabarti R, Chen M, Chakrabarti S. Transcriptional co-activator p300 regulates glucose induced gene expression in the endothelial cells. Am. J. Physiol. Endocrinol. Metab. — 2010. — Vol. 298. — P. E127-E137. doi: 10.1152/ajpendo.00432.2009.
Horinouchi T, Hoshi A, Harada T, Higa T, Karki S, Terada K, et al.Endothelin‑1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells. Br. J. Pharmacol. — 2016. — Vol. 173, N. 6. — P. 1018-1032. doi: 10.1111/bph.13406.
Markowicz-Piasecka M, Huttunen KM, Sadkowska A, Sikora J. Pleiotropic activity of metformin and its sulfonamide derivatives on vascular and platelet haemostasis. Molecules. — 2019. — Vol. 25, N. 1. — P. 125. doi:10.3390/molecules25010125.
Пушкарев ВМ, Соколова ЛК, Пушкарев ВВ, Тронько НД. Роль АМРК и mTOR в развитии инсулинорезистентности и диабета 2 типа. Mеханизм действия метформина (обзор литературы).
Проблемы эндокринной патологии. — 2016. — № 3. — C. 77-90. (Pushkarev VM, Sokolova LK, Pushkarev VV, Tronko MD. The role of AMPK and mTOR in the developmentof insulin resistance and type 2 diabetes. The mechanism of metformin action (literature review). Prob Endocrine Pathol. 2016. — N. 3. — P. 77-90.)
Abdelgadir E, Ali R, Rashid F, Bashier A. Effect of metformin on different non-diabetes related conditions, a special focus on malignant conditions: review of literature. J. Clin. Med. Res. — 2017. — Vol. 9, N. 5. — P. 388-395. doi:10.14740/jocmr2922e.
Yang X, Xu Z, Zhang C, Cai Z, Zhang J. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. Biochim. Biophys. Acta. — 2017. — Vol. 1863, N. 8. — P. 1984-1990. doi: 10.1016/j.bbadis.2016.09.019.
Valentine RJ, Coughlan KA, Ruderman NB, Saha AK. Insulin inhibits AMPK activity and phosphorylates AMPK Ser485/491 through Akt in hepatocytes, myotubes and incubated rat skeletal muscle. Arch. Biochem. Biophys. — 2014. — Vol. 562. — P. 62-69. doi: 10.1016/j.abb.2014.08.013.
Pushkarev VV, Sokolova LK, Pushkarev VM, Belchina YB, Vatseba TS, Tronko ND. Effect of combined treatment with insulin and other hypoglycemic drugs on 5’AMP-activated protein kinase activity in lymphocytes in patients with diabetes mellitus. Проблеми ендокринної патології. — 2019. — № 3. — С. 74-82.
Pscherer S, Freude T, Forst T, Nussler AK, Braun KF, Ehnert S. Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics. Diabetol. Metab. Syndr. — 2013. — Vol. 5, N. 1. — P. 48. doi:10.1186/1758-5996-5-48.
Xiao H, Zhang J, Xu Z, Feng Y, Zhang M, Liu J, et al. Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci.Rep. — 2016. — Vol. 6. — P. 28597. doi: 10.1038/srep28597.
Tong X, Ma H, Amadi SW, Ma L, Wu G. Reno-protection of G004, a novel anti-diabetic sulfonylurea in db/db mice. Naunyn Schmiedebergs Arch. Pharmacol. — 2015. — Vol. 388, N. 8. — P. 831-841. doi:10.1007/s00210-015-1112-7.
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and metaanalysis. JAMA. — 2018. — Vol. 319, N. 15. — P. 1580-1591. doi:10.1001/jama.2018.3024.
Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc. Diabetol. — 2017. — Vol. 16, N. 1. — P. 138. doi:10.1186/s12933-017-0621-8.
Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, et al. The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus. Intern. Med. — 2018. — Vol. 57, N. 15. — P. 2147-2156. doi:10.2169/internalmedicine.0701-17.
Zainordin NA, Hatta SFWM, Mohamed Shah FZ, Rahman TA, Ismail N, Ismail Z, et al. Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established ischemic heart disease (EDIFIED). J. Endocr. Soc. — 2019. — Vol. 4, N. 1. — P. bvz017. doi:10.1210/jendso/bvz017.
Gaspari T, Spizzo I, Liu H, Hu Y, Simpson RW, Widdop RE, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diab. Vasc. Dis. Res. — 2018. — Vol. 15, N. 1. — P. 64-73. doi:10.1177/1479164117733626.
Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ, Zhou Q, et al. Sitagliptin inhibits endothelin‑1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. Int. J. Mol. Med. — 2016. — Vol. 37, N. 6. — P. 1558-1566. doi: 10.3892/ijmm.2016.2578.
Pharmacy Practice News Staff. Diabetes meds containing saxagliptin and alogliptin linked to increased HF. Pharmacy Practice News. — 2016.